15 minute read
Oct. 10, 2023
A 1990’s Abbott Candidate Revived by a Biotech for Renal Health
atrasentan
oral ETA receptor antagonist Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome ligand-based design from prior ETAR antagonists Acquisition announcement, June 12, 2023 Abbott Labs (AbbVie) / Chinook Therapeutics
Author:
Editor: